Deciphering breast cancer: from biology to the clinic

E Nolan, GJ Lindeman, JE Visvader - Cell, 2023 - cell.com
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Breast cancer: an up‐to‐date review and future perspectives

R Hong, B Xu - Cancer communications, 2022 - Wiley Online Library
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention

EM Stoffel, RE Brand, M Goggins - Gastroenterology, 2023 - Elsevier
Pancreatic cancer usually results in poor survival with limited options for treatment, as most
affected individuals present with advanced disease. Early detection of preinvasive …

[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …

HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale… - … England Journal of …, 2021 - Mass Medical Soc
Background Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers with
defects in homologous recombination repair by synthetic lethality. New therapies are …

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline☆

C Sessa, J Balmaña, SL Bober… - Annals of …, 2023 - annalsofoncology.org
Hereditary breast and ovarian cancer syndrome (HBOC) is clinically defined by family
history criteria, and molecularly defined by identification of germline pathogenic variants …

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

S Yadav, NJ Boddicker, J Na, EC Polley… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To estimate the risk of contralateral breast cancer (CBC) among women with
germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 …

Germline testing in patients with breast cancer: ASCO–Society of Surgical Oncology guideline

I Bedrosian, MR Somerfield, MI Achatz… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE To develop recommendations for germline mutation testing for patients with
breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to …

What is known about breast cancer in young women?

JW Zhu, P Charkhchi, S Adekunte, MR Akbari - Cancers, 2023 - mdpi.com
Simple Summary Breast cancer is the most common cancer affecting women under 40 years
of age worldwide, with an increasing number of cases diagnosed each year. Despite this …